• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过与p53反式激活结构域和启动子的多次接触,表皮生长因子受体的上调促进了肺癌细胞对功能获得性p53的成瘾。

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.

作者信息

Vaughan Catherine A, Pearsall Isabella, Singh Shilpa, Windle Brad, Deb Swati P, Grossman Steven R, Yeudall W Andrew, Deb Sumitra

机构信息

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.

出版信息

Oncotarget. 2016 Mar 15;7(11):12426-46. doi: 10.18632/oncotarget.6998.

DOI:10.18632/oncotarget.6998
PMID:26820293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4914296/
Abstract

Human lung cancers harboring gain-of-function (GOF) p53 alleles express higher levels of the epidermal growth factor receptor (EGFR). We demonstrate that a number of GOF p53 alleles directly upregulate EGFR. Knock-down of p53 in lung cancer cells lowers EGFR expression and reduces tumorigenicity and other GOF p53 properties. However, addiction of lung cancer cells to GOF p53 can be compensated by overexpressing EGFR, suggesting that EGFR plays a critical role in addiction. Chromatin immunoprecipitation (ChIP) using lung cancer cells expressing GOF p53 alleles showed that GOF p53 localized to the EGFR promoter. The sequence where GOF p53 is found to interact by ChIP seq can act as a GOF p53 response element. The presence of GOF p53 on the EGFR promoter increased histone H3 acetylation, indicating a mechanism whereby GOF p53 enhances chromatin opening for improved access to transcription factors (TFs). ChIP and ChIP-re-ChIP with p53, Sp1 and CBP histone acetylase (HAT) antibodies revealed docking of GOF p53 on Sp1, leading to increased binding of Sp1 and CBP to the EGFR promoter. Up-regulation of EGFR can occur via GOF p53 contact at other novel sites in the EGFR promoter even when TAD-I is inactivated; these sites are used by both intact and TAD-I mutated GOF p53 and might reflect redundancy in GOF p53 mechanisms for EGFR transactivation. Thus, the oncogenic action of GOF p53 in lung cancer is highly dependent on transactivation of the EGFR promoter via a novel transcriptional mechanism involving coordinated interactions of TFs, HATs and GOF p53.

摘要

携带功能获得性(GOF)p53等位基因的人类肺癌表达更高水平的表皮生长因子受体(EGFR)。我们证明,一些GOF p53等位基因直接上调EGFR。肺癌细胞中p53的敲低降低了EGFR表达,并降低了致瘤性和其他GOF p53特性。然而,肺癌细胞对GOF p53的依赖性可以通过过表达EGFR来补偿,这表明EGFR在依赖性中起关键作用。使用表达GOF p53等位基因的肺癌细胞进行的染色质免疫沉淀(ChIP)表明,GOF p53定位于EGFR启动子。通过ChIP seq发现GOF p53相互作用的序列可作为GOF p53反应元件。EGFR启动子上GOF p53的存在增加了组蛋白H3的乙酰化,表明GOF p53增强染色质开放以改善转录因子(TFs)的可及性的机制。用p53、Sp1和CBP组蛋白乙酰转移酶(HAT)抗体进行的ChIP和ChIP-re-ChIP显示,GOF p53与Sp1对接,导致Sp1和CBP与EGFR启动子的结合增加。即使TAD-I失活,EGFR的上调也可通过GOF p53在EGFR启动子其他新位点的接触而发生;这些位点被完整的和TAD-I突变的GOF p53所利用,可能反映了GOF p53介导EGFR反式激活机制中的冗余性。因此,GOF p53在肺癌中的致癌作用高度依赖于通过涉及TFs、HATs和GOF p53协同相互作用的新转录机制对EGFR启动子的反式激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/2248ddd05730/oncotarget-07-12426-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/2f3d134c83d7/oncotarget-07-12426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/eeb1107b4862/oncotarget-07-12426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/fcd311acea72/oncotarget-07-12426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/a32bf383cc52/oncotarget-07-12426-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/02c4f8eadcb1/oncotarget-07-12426-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/b77d389f91ed/oncotarget-07-12426-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/17c4a8284b41/oncotarget-07-12426-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/98c7017f9ca1/oncotarget-07-12426-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/f9d24fb62e0c/oncotarget-07-12426-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/2248ddd05730/oncotarget-07-12426-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/2f3d134c83d7/oncotarget-07-12426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/eeb1107b4862/oncotarget-07-12426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/fcd311acea72/oncotarget-07-12426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/a32bf383cc52/oncotarget-07-12426-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/02c4f8eadcb1/oncotarget-07-12426-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/b77d389f91ed/oncotarget-07-12426-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/17c4a8284b41/oncotarget-07-12426-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/98c7017f9ca1/oncotarget-07-12426-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/f9d24fb62e0c/oncotarget-07-12426-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfaa/4914296/2248ddd05730/oncotarget-07-12426-g010.jpg

相似文献

1
Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.通过与p53反式激活结构域和启动子的多次接触,表皮生长因子受体的上调促进了肺癌细胞对功能获得性p53的成瘾。
Oncotarget. 2016 Mar 15;7(11):12426-46. doi: 10.18632/oncotarget.6998.
2
Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.功能获得性 p53 突变体上调 CXC 趋化因子并增强细胞迁移。
Carcinogenesis. 2012 Feb;33(2):442-51. doi: 10.1093/carcin/bgr270. Epub 2011 Nov 22.
3
Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.功能获得性p53激活多种信号通路以诱导肺癌细胞发生致癌性。
Mol Oncol. 2017 Jun;11(6):696-711. doi: 10.1002/1878-0261.12068. Epub 2017 May 8.
4
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.p53 突变体通过 CBP 和 STAT 在 NF-κB2 启动子上的结合以及获得功能活性,诱导 H1299 细胞中 NF-κB2 的转录。
Arch Biochem Biophys. 2012 Feb 1;518(1):79-88. doi: 10.1016/j.abb.2011.12.006. Epub 2011 Dec 16.
5
Allele specific gain-of-function activity of p53 mutants in lung cancer cells.肺癌细胞中 p53 突变体的等位基因特异性获得性功能。
Biochem Biophys Res Commun. 2012 Nov 9;428(1):6-10. doi: 10.1016/j.bbrc.2012.09.029. Epub 2012 Sep 16.
6
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.肿瘤衍生突变型 p53 的致癌性可通过招募 PLK3 得到增强。
Nat Commun. 2021 Jan 29;12(1):704. doi: 10.1038/s41467-021-20928-8.
7
Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes.p53缺失诱导正常人角质形成细胞中表皮生长因子受体启动子活性。
Oncogene. 2008 Jul 17;27(31):4315-23. doi: 10.1038/onc.2008.65. Epub 2008 Apr 7.
8
Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.人p53对人表皮生长因子受体启动子的转录激活作用。
Mol Cell Biol. 1996 Nov;16(11):6009-19. doi: 10.1128/MCB.16.11.6009.
9
Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.功能获得性突变 p53 通过靶向转录因子 FOXO3a 和 FOXM1 促进头颈部鳞状细胞癌细胞的致癌潜能。
Oncogene. 2018 Mar;37(10):1279-1292. doi: 10.1038/s41388-017-0032-z. Epub 2017 Dec 22.
10
Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.p53/Sp1 调控失调导致肺癌中 DNA 甲基转移酶-1 的过表达。
Cancer Res. 2010 Jul 15;70(14):5807-17. doi: 10.1158/0008-5472.CAN-09-4161. Epub 2010 Jun 22.

引用本文的文献

1
Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.致癌性p53通过复制赋予可靶向增殖优势的DNA复制叉,在肺癌细胞中诱导有丝分裂错误。
Res Sq. 2025 Aug 13:rs.3.rs-7303237. doi: 10.21203/rs.3.rs-7303237/v1.
2
TET1 functions as a tumor suppressor in lung adenocarcinoma through epigenetic remodeling and immune modulation.TET1通过表观遗传重塑和免疫调节在肺腺癌中发挥肿瘤抑制作用。
Epigenetics Chromatin. 2025 Aug 11;18(1):53. doi: 10.1186/s13072-025-00617-2.
3
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.

本文引用的文献

1
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.功能获得性突变型p53通过抑制AMPK激活促进细胞生长和癌细胞代谢。
Mol Cell. 2014 Jun 19;54(6):960-974. doi: 10.1016/j.molcel.2014.04.024. Epub 2014 May 22.
2
Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites.功能获得性突变型p53与双向启动子的优先结合,以及ETS1和GABPA与多个结合位点的协同结合。
Oncotarget. 2014 Jan 30;5(2):417-27. doi: 10.18632/oncotarget.1708.
3
Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4.
突变型 p53-ENTPD5 调控钙网织蛋白/钙结合蛋白循环:抑制整合素-α5 驱动转移的可用药靶。
J Exp Clin Cancer Res. 2023 Aug 10;42(1):203. doi: 10.1186/s13046-023-02785-z.
4
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.不同癌症类型中 TP53 突变对细胞周期相关基因表达的不同影响。
Sci Rep. 2023 Mar 24;13(1):4868. doi: 10.1038/s41598-023-32092-8.
5
Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration.人 E26 转录因子 1 和特定蛋白 1 之间的磷酸化介导的相互作用对于肿瘤细胞迁移是必需的。
Acta Biochim Biophys Sin (Shanghai). 2022 Oct 25;54(10):1441-1452. doi: 10.3724/abbs.2022148.
6
Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.p53 对非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂敏感性的影响。
Sci Rep. 2021 Oct 4;11(1):19667. doi: 10.1038/s41598-021-99267-z.
7
A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors.非小细胞肺癌中驱动依赖从表皮生长因子受体(EGFR)向Notch1的可逆转变作为酪氨酸激酶抑制剂耐药的一个原因
Cancers (Basel). 2021 Apr 22;13(9):2022. doi: 10.3390/cancers13092022.
8
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.肿瘤衍生突变型 p53 的致癌性可通过招募 PLK3 得到增强。
Nat Commun. 2021 Jan 29;12(1):704. doi: 10.1038/s41467-021-20928-8.
9
p53's Extended Reach: The Mutant p53 Secretome.p53 的延伸作用:突变 p53 分泌组。
Biomolecules. 2020 Feb 15;10(2):307. doi: 10.3390/biom10020307.
10
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?利用肺癌中 p53 突变体的弱点 - 聚焦蛋白酶体:以旧敌为新招?
Cancer Biol Ther. 2020 Apr 2;21(4):293-302. doi: 10.1080/15384047.2019.1702403. Epub 2020 Feb 10.
CBP 和 p300 对组蛋白 H3 和 H3/H4 的乙酰化在特异性和选择性上的差异。
Biochemistry. 2013 Aug 27;52(34):5746-59. doi: 10.1021/bi400684q. Epub 2013 Aug 12.
4
Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.突变型p53通过上调受体蛋白酪氨酸激酶Axl在肺癌中的功能获得性活性
Genes Cancer. 2012 Jul;3(7-8):491-502. doi: 10.1177/1947601912462719.
5
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.人类癌蛋白 MDM2 通过与抑制元件-1 沉默转录因子相互作用激活 Akt 信号通路,赋予癌细胞生存优势。
Cell Death Differ. 2013 Apr;20(4):558-66. doi: 10.1038/cdd.2012.153. Epub 2012 Dec 14.
6
Mutant p53: one name, many proteins.突变型 p53:一个名字,多种蛋白。
Genes Dev. 2012 Jun 15;26(12):1268-86. doi: 10.1101/gad.190678.112.
7
Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.人类癌蛋白MDM2上调NF-κB2前体p100的表达,赋予肺细胞生存优势。
Genes Cancer. 2011 Oct;2(10):943-55. doi: 10.1177/1947601911436008.
8
Mutant p53 cooperates with ETS2 to promote etoposide resistance.突变型 p53 与 ETS2 协同作用促进依托泊苷耐药。
Genes Dev. 2012 Apr 15;26(8):830-45. doi: 10.1101/gad.181685.111.
9
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体:RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
10
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.突变型 p53 通过甲羟戊酸途径破坏乳腺组织的结构。
Cell. 2012 Jan 20;148(1-2):244-58. doi: 10.1016/j.cell.2011.12.017.